Evidence map›Paper›PMID 37370725›Full record

ReviewCancers2023

Insights into the Impact of Hesitancy on Cancer Care and COVID-19.

Nathan Visweshwar, Juan Felipe Rico, Irmel Ayala, Michael Jaglal, Damian A Laber, Mohammad Ammad-Ud-Din, Lubomir Sokol, Eduardo Sotomayor, Arumugam Manoharan

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Nathan VisweshwarDepartment of Medicine, University of South Florida, Tampa, FL 33612, USA.
Juan Felipe RicoDepartment of Pediatric Hematology, University of South Florida, Tampa, FL 33612, USA.ORCID 0000-0002-7522-9542
Irmel AyalaDepartment of Pediatric Hematology, Johns Hopkins All Children's Hospital, St. Petersburg, FL 33701, USA.
Michael JaglalDepartment of Satellite and Community Oncology and Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Damian A LaberFACP Department of Satellite and Community Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.ORCID 0000-0003-1041-4429
Mohammad Ammad-Ud-DinDepartment of Hematology and Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Lubomir SokolDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Eduardo SotomayorMalignant Oncology, Tampa General Hospital, Tampa, FL 33607, USA.
Arumugam ManoharanFRACP, FRCPA Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2217, Australia.ORCID 0000-0003-0721-408X
Moffitt Cancer Center · USUniversity of South Florida · USJohns Hopkins University · USTampa General Hospital · USUniversity of Wollongong · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

World Health Organization findings indicate that the COVID-19 pandemic adversely affected cancer diagnosis and management. The COVID-19 pandemic disrupted the optimal management of outpatient appointments, scheduled treatments, and hospitalizations for cancer patients because of hesitancy among patients and health-care providers. Travel restrictions and other factors likely affected medical, surgical, and radiation treatments during the COVID-19 pandemic. Cancer patients were more likely to be affected by severe illness and complications if they contracted COVID-19. A compromised immune system and comorbidities in cancer patients may have contributed to this increased risk. Hesitancy or reluctance to receive appropriate therapy or vaccination advice might have played a major role for cancer patients, resulting in health-care deficits. The purpose of this review is to evaluate the impact of COVID-19 on screening, entry into clinical trials, and hesitancy among patients and health-care professionals, limiting adjuvant and metastatic cancer treatment.

Indexed as

cancerCOVID-19hesitancymanagementtreatment

Identifiers

PMID37370725
PMCPMC10296298
OpenAlexW4380079330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.